Form D · Biotechnology
GEMA DIAGNOSTICS, INC.
Ann Arbor, MI · CIK 0001355650
Offering snapshot reported Mar 27, 2013 · SEC filing
- Reported sold
- $2.67M Offering amount: $3.75M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Mar 15, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 27, 2013 | Initial | $2,665,127 | No comparison | 7 | SEC filing |
| Feb 13, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06, 46
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-194073
Source: Form D, filed Mar 27, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lindsay Douglas Aspegren | Director |
| Charles Robert Burke | Director |
| Jose Bernardo Cibelli | Director |
| David Lyman Repp | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
206 S. Fifth Avenue, Suite 550
Ann Arbor, MI, 48104
Ann Arbor, MI, 48104